Azzet reports on three stocks with price moving updates today.
4D Medical soars on US deal
Shares in 4DMedical (ASX: 4DX) were over 14% higher in early trading today after the medical technology company told the market U.S. San Diego Health (UCSD) had started the clinical use of its CT:VQ respiratory imaging technology.
Given that the company is focussed on accelerating the rollout of its newly-FDA approved CT:VQ imaging product - through strategic partnerships and new contracts – the market was encouraged by the update.
UCSD joins prestigious company - Stanford University, University of Miami, and Cleveland Clinic - as the fourth U.S. academic medical centre to deploy the technology within only four months of CT:VQ receiving US Food & Drug Administration thumbs up.
Management was quick to frame today’s update as further validation 4DMedical’s commercialisation strategy.
Dr Jonathan Chung, Chief of Cardiothoracic Imaging at UC San Diego Health, told the market that CT:VQ enables functional ventilation and perfusion evaluation layered on top of traditional CT scans, improving diagnostic reach.
Since receiving FDA approval last August, the company has been one of the ASX’s fastest-growing stocks, up 777% in the last year and up 151% in the last month.
Based on current momentum, 2026 is shaping up to be a transformative year for the company.
While recent share price appreciation may have investors wondering whether the stock is overvalued, the prospect of increased product adoption and long-term commercial growth would suggest otherwise.
However, despite the stock’s meteoric run up, recent share price volatility may spook some investors.
Shares in the company closed down 10.13% at $4.08 on Monday - making it the worst-performing stock on the ASX 200 for the day - a sharp reversal from Friday when the stock led the index with a 15.52% gain.
4DMedical is not a heavily shorted stock, which may reflect the lack of shares available to borrow.
The update follows revelations 4DMedical also has a global distribution deal with Philips, which gives it access to a large number of hospitals around the world.
4DMedical has a market capitalisation of $2.2 billion; the stock has outperformed the ASX200 by 770% in the last year.
The stock appears to be in a strong bullish trend confirmed by multiple indicators.
Specifically, a five-day moving average of the stock price is above the 20 and 50-day moving averages.
Additionally, a long-term bullish signal is offered by the 200-day moving average which is trending higher.
The consensus recommendation is Strong Buy.
Manuka Resources rallies after flagging Cobar restart and Taranaki VTM project
Shares in Manuka Resources (ASX: MKR) were trading over 22% higher heading into lunch today after the ASX/NZX-listed producer, developer and explorer - with precious metals assets in the Cobar Basin and iron ore and critical minerals assets in New Zealand (NZ) - revealed plans to restart silver-gold production at Wonawinta project and Mt Boppy in Q2 2026.
The company is focused on bringing its Cobar Basin precious metal assets back online and has laid out a 10-year mine plan targeting 19Moz of silver from the Wonawinta open pits and ROM stockpiles, and 46koz of gold from the Mt Boppy open pit and Wonawinta/Mt Boppy stockpiles.
Restart costs are expected to come in at $18.9 million, including the addition of a deslime circuit to the Wonawinta processing plant.
Average earnings are projected at around $106 million, resulting in a net present value (NPV) of A$668 million and an internal rate of return (IIR) of around 1,096%, based on $107.50/oz silver.
Meanwhile, the company is also advancing the Taranaki VTM (vanadium, titanium, magnetite) Project in NZ, which will remain completely unhedged.
Boasting a 3.2Bt VTM resource, the Taranaki Project – which completed a pre-feasibility study (PFS) in March 2025 – has outlined a 5Mtpa production of critical minerals bearing iron ore concentrate from seafloor iron sands deposits.
This project is undergoing NZ’s fast-track approvals process, with a decision expected by 18 March 2026.
The company aims to commence a Bankable Feasibility Study in 2026.
The share price has doubled since the company announced a major new drilling program had commenced at Mt Boppy and Pipeline Ridge in mid-December.
Historically, Mt Boppy delivered around 500,000oz Au grading about 15g/t Au from the existing pit in its relatively brief, active mine life.
Since then the company has signed a term sheet with the Nebari Natural Resources Credit Fund for a US$22.5 million senior secured loan facility, which follows a recent $15 million capital raising.
Management recently told the market that Manuka’s cash flow forecasts were highly leveraged to the silver price (every US$1.00 increase in the price generates an additional $20m for the company on a project basis).
“The current silver price environment provides an excellent tailwind for the Company to commence production next year,” Manuka noted.
Manuka Resources has a market capitalisation of $189 million; the share price is up 431% in one year and up 121% in the last month.
The stock appears to be in a strong bullish trend confirmed by multiple indicators.
Specifically, a five-day moving average of the stock price is above the 20 and 50-day moving averages.
Additionally, a long-term bullish signal is offered by the 200-day moving average which is trending higher.
There is no consensus recommendation for this stock.
Greatland Resources leaps on quarterly production update
Shares in Greatland Resources (ASX: GGP; FTSE AIM 100: GGP.L) were up over 5% in afternoon trading after the gold and copper producer released a standout December quarterly update.
The miner reported production of 86,273 ounces of gold and 3,528 tonnes of copper, taking first-half (H1) 2026 financial year (FY26) output to 167,163 ounces of gold, alongside a substantial cash build.
This marks a clear improvement on the September quarter when Greatland produced 80,890 ounces of gold and 3,366 tonnes of copper.
With H1 FY26 production at 167,163 ounces of gold and 6,894 tonnes of copper, the company is on track operationally as it continues integrating the Telfer and Havieron assets in WA’s Paterson Province.
Sales for the quarter totalled 72,212 ounces of gold and 3,301 tonnes of copper.
While all-in sustaining costs (AISC) are still being finalised, management expects to release its full December quarterly activities report later this month.
Despite capital expenditure and a $46 million stamp duty payment linked to the Telfer–Havieron acquisition, cash at 31 December rose to $948 million, up $198 million over the quarter.
Excluding the stamp duty payment, Greatland said the cash-build would have been $244 million.
On pricing, the company said it retains full upside exposure to the gold price, with some downside protection through gold put options.
Meanwhile the company remains debt-free and largely unhedged, retaining full exposure to gold prices, and confirmed it will release full cost metrics, including AISC, later in January.
While the share price has been bouncing higher since late October, the stock staged a strong ascent mid-December after entering into a multi-stage farm-in and joint venture agreement with Rincon Resources Ltd covering a large portion of Rincon’s Telfer South tenure.
This agreement expands the exploration footprint south of Greatland's 100% owned Telfer gold-copper mine, placing it within 30 kilometres of the Telfer processing facility.
Under the agreement, Greatland can earn an initial 51% interest by funding $2 million of exploration over 36 months, including a minimum commitment of $300,000 in the first year.
Greatland Resources has a market capitalisation of $7.2 billion; and the share price is up 73% in one year and up 36% in the last month.
The consensus recommendation is Moderate Buy.
